Internal Medicine, Pulmonary Disease · Council Bluffs, IA
NPI
1104967090
Since 2007
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
1 Edmundson Pl, Suite 312
Council Bluffs, IA, 51503
Phone (712) 396-4295
Groups this clinician bills Medicare through
Medicare paid, 2024
$131K
7,305 services
Medicare patients, 2024
516
Average age 75
Drug cost, 2024
$2.4M
2,869 prescriptions
Company payments, 2025
$5,580
From 21 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by John G Southard was code 95004 (test - miscellaneous), 2,870 times for 41 patients. In total John G Southard billed 7,305 services in 17 codes, and Medicare paid $131K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 95004 Test - Miscellaneous | Office | 2,870 | 41 | $2.48 | $7,111 |
| 95165 Treatment - Miscellaneous | Office | 1,352 | 62 | $9.82 | $13K |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 868 | 114 | $0.73 | $630 |
| 99214 Office E&M - Established | Office | 865 | 445 | $88.23 | $76K |
| 95117 Treatment - Miscellaneous | Office | 843 | 56 | $7.99 | $6,733 |
| 99204 Office E&M - New | Office | 122 | 122 | $115.06 | $14K |
| 94060 Pulmonary Function Testing | Office | 72 | 71 | $26.90 | $1,937 |
| 94727 Pulmonary Function Testing | Office | 72 | 71 | $30.85 | $2,221 |
| 94729 Pulmonary Function Testing | Office | 72 | 71 | $39.06 | $2,813 |
| 96372 Injection Administration | Office | 68 | 33 | $10.27 | $698 |
By year: 2022 $167K for 8,716 services; 2023 $145K for 7,807 services; 2024 $131K for 7,305 services.
Medicare prescription drug claims, 2024
In 2024, the drug John G Southard prescribed most often to Medicare patients was Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter), with 753 prescriptions and refills. In total John G Southard wrote 2,869 Medicare prescriptions that cost $2.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 753 | 897 | 125 | $571K |
| Albuterol Sulfate Hfa Albuterol Sulfate | 315 | 350 | 80 | $7,125 |
| Breo Ellipta Fluticasone/Vilanterol | 284 | 342 | 45 | $135K |
| Prednisone Generic | 213 | 247 | 124 | $751 |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | 126 | 146 | 22 | $92K |
| Levofloxacin Generic | 85 | 85 | 64 | $385 |
| Montelukast Sodium Generic | 75 | 107 | 11 | $358 |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | 67 | 101 | 17 | $47K |
| Ventolin Hfa Albuterol Sulfate | 55 | 63 | 16 | $3,732 |
| Epinephrine Generic | 52 | 52 | 49 | $8,073 |
| Doxycycline Hyclate Generic | 40 | 40 | 12 | $411 |
| Omeprazole Generic | 38 | 42 | Under 11 | $118 |
| Pirfenidone Generic | 35 | 35 | Under 11 | $59K |
| Dupixent Pen Dupilumab | 31 | 35 | Under 11 | $130K |
| Stiolto Respimat Tiotropium Br/Olodaterol Hcl | 31 | 41 | Under 11 | $19K |
Brand drugs: 1,779 claims; generic drugs: 1,090 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid John G Southard $5,580 ($5,580 in general payments such as food, travel and fees) from 21 companies. The largest payer was Viatris Specialty LLC with $3,961.
| Company | Payments | Amount |
|---|---|---|
| Viatris Specialty LLC | 22 | $3,961 |
| AstraZeneca Pharmaceuticals LP AZN | 11 | $473 |
| Abbvie Inc. ABBV | 9 | $176 |
| Verona Pharma, Inc. VRNA | 14 | $142 |
| GlaxoSmithKline, LLC. GSK | 13 | $135 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $109 |
| Regeneron Healthcare Solutions, Inc. REGN | 6 | $99.99 |
| Insmed, Inc. INSM | 4 | $68.05 |
| Harmony Biosciences LLC HRMY | 3 | $62.35 |
| Amgen Inc. AMGN | 3 | $55.42 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.